Ng Carey J, Bourquard Noam, Hama Susan Y, Shih Diana, Grijalva Victor R, Navab Mohamad, Fogelman Alan M, Reddy Srinivasa T
Atherosclerosis Research Unit, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095, USA.
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1368-74. doi: 10.1161/ATVBAHA.106.134189. Epub 2007 Apr 19.
We have previously reported that human paraoxonase 3 (PON3) is an HDL-associated protein capable of preventing LDL oxidation in vitro. The objective of the present study was to determine whether elevated levels of human PON3 in mice could protect against the progression of atherosclerosis in vivo.
Twenty-six week-old apolipoprotein E-deficient mice were injected with 3x10(11) particles of adenovirus expressing either GFP alone (AdGFP) or together with human PON3 (AdPON3). Three weeks after injection, lesion area was significantly lower in AdPON3-treated mice compared with AdGFP controls. Serum from AdPON3 mice contained significantly lower levels of lipid hydroperoxides and exhibited an enhanced potential to efflux cholesterol from cholesterol-loaded macrophages. In addition, LDL was less susceptible to oxidation, whereas HDL was more capable of protecting against LDL oxidation. Exogenous human PON3 was not detected in the serum or HDL and more surprisingly we demonstrate that endogenous mouse PON3 is not associated with HDL, suggesting that the antioxidant function of PON3 is at the cellular level in mice.
This study demonstrates for the first time that PON3 enhances the antiatherogenic capacity of serum and protects against the progression of atherosclerosis in vivo.
我们之前曾报道,人对氧磷酶3(PON3)是一种与高密度脂蛋白(HDL)相关的蛋白质,在体外能够防止低密度脂蛋白(LDL)氧化。本研究的目的是确定小鼠体内人PON3水平升高是否能在体内预防动脉粥样硬化的进展。
给26周龄的载脂蛋白E缺陷小鼠注射3×10¹¹个单独表达绿色荧光蛋白(GFP)或与人类PON3一起表达(AdPON3)的腺病毒颗粒。注射三周后,与AdGFP对照组相比,AdPON3处理的小鼠病变面积显著降低。AdPON3小鼠血清中的脂质氢过氧化物水平显著降低,并且从胆固醇负载的巨噬细胞中流出胆固醇的能力增强。此外,LDL更不易被氧化,而HDL更有能力防止LDL氧化。在血清或HDL中未检测到外源性人PON3,更令人惊讶的是,我们证明内源性小鼠PON3不与HDL相关,这表明PON3的抗氧化功能在小鼠体内是在细胞水平发挥作用。
本研究首次证明PON3增强了血清的抗动脉粥样硬化能力,并在体内预防动脉粥样硬化的进展。